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Abstract: MRI can favor clinical diagnosis providing morphological and functional information
of several neurological disorders. This paper deals with the problem of exploiting both data,
in a combined way, to develop a tool able to support clinicians in the study and diagnosis of
Alzheimer’s Disease (AD). In this work, 69 subjects from the ADNI open database, 33 AD patients
and 36 healthy controls, were analyzed. The possible existence of a relationship between brain
structure modifications and altered functions between patients and healthy controls was investigated
performing a correlation analysis on brain volume, calculated from the MRI image, the clustering
coefficient, derived from fRMI acquisitions, and the Mini Mental Score Examination (MMSE).
A statistically-significant correlation was found only in four ROIs after Bonferroni’s correction.
The correlation analysis alone was still not sufficient to provide a reliable and powerful clinical tool
in AD diagnosis however. Therefore, a machine learning strategy was studied by training a set of
support vector machine classifiers comparing different features. The use of a unimodal approach led
to unsatisfactory results, whereas the multimodal approach, i.e., the synergistic combination of MRI,
fMRI, and MMSE features, resulted in an accuracy of 95.65%, a specificity of 97.22%, and a sensibility
of 93.93%.
Keywords: Alzheimer’s disease; biomedical image processing; biomedical signal processing;
cognitive science; correlation analysis; graph theory; magnetic resonance imaging; medical diagnostic
imaging; SVM
1. Introduction
Magnetic Resonance Imaging (MRI) and functional Magnetic Resonance Imaging (fMRI) of the
brain are popular methods of inquiry in neuroscience [1]. These techniques are exploited to obtain
important morphological and functional information in a non-invasive way [2]. MRI can probe the
structural environment, whilst fMRI can be employed to detect changes in the Blood Oxygenation
Level-Dependent (BOLD) signal [3]. One of the most important limitations in MRI is the Signal-to-Noise
Ratio (SNR) [3], which is influenced by the static magnetic field B0 and other parameters, e.g., time echo,
time repetition, flip angle, slice thickness, and matrix size [4]. The adjustment of the cited parameters
provides a good image reconstruction with a high SNR. The imaging modalities, such as computed
tomography and MRI, ensure good tissue contrast and spatial resolution [2,5], which favor an adequate
tissue segmentation. In fact, the possibility of detecting structural abnormalities depends on the
segmentation accuracy, which in turn may improve the diseases’ diagnosis [6–8].
The segmentation can be performed manually or automatically with open source brain imaging
software, e.g., SPM (fil.ion.ucl.ac.uk), FSL (fmrib.ox.ac.uk), or FreeSurfer (surfer.nmr.mgh.harvard.edu).
By means of these software programs, it is possible to recognize and to extract the data of the brain
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features to investigate, such as the Grey Matter Volume (GMV). Typically, in clinical practice, the GMV
is quantified to assess the degree of cerebral atrophy and to monitor the neuropathologies’ state [9].
One of the most prevalent neurodegenerative disorders is Alzheimer’s Disease (AD).
This pathology is characterized by a severe derangement of cognitive functions and structural changes
within the brain. The pathological hallmarks are the accumulation of β-amyloid (Aβ1-42) plaques
and tau tangles, which cause cognitive and structural damage [10]. Several studies exploited fMRI
to diagnose neurological pathology, such as schizophrenia [11], AD, and Mild Cognitive Impairment
(MDI) [12]. In functional imaging, the BOLD signal reflects the activity degree of brain areas and can
be used to analyze maps of functional connectivity or network measures [3]. The most important
issue of fMRI is the physiological noise, which derives from cardiac, respiratory and head movements.
In fact, BOLD signal can be corrupted by this kind of noise since it fluctuates within the same frequency
band [13,14]. In commercial software for brain imaging, there are several automatic functionalities to
remove these artifacts, which can alter the BOLD signal and its relevance, such as the Component-based
method (CompCor) [15].
New approaches founded on graph theory [16,17] have been proposed to investigate in vivo
alterations in functional and structural cerebral networks by means of fMRI. Several studies have shown
that graph theory is sensitive in providing network measurements of psychiatric and neurological
disease, as in AD diagnosis [18,19].
In the literature, several research groups have focused on the use of MRI and fMRI to identify
and stress the differences between AD and healthy subjects. Some work from the literature
studied exclusively the anatomical structure, to highlight volume brain modifications [5,20], whereas
others analyzed only functional aspect to assess the cognitive status of the patients [21,22]. Other
studies showed the feasible correlation between these two aspects [23,24], but using other types of
measurements. To the best of the author’s knowledge, none of the cited work ever carried out an
investigation about the possible correlation between the ROI volumes, retrieved from MRI, and the
graph connectivity measurements, derived from fMRI acquisitions.
Besides the pure statistical approach, from the meta-analysis of the literature, it is possible to
identify the trend of employing machine learning to classify AD patients from HCs. On the one
hand, many of them used only structural information obtained from MRI images [25,26]; whilst,
on the other hand, others used both structural and functional information to train the classifier [27,28].
The cited works faced the problem of recognizing diseased subjects using a reduced number of
features, which can be derived by a single clinical exam. It should be pointed out that the functional
information was derived from PET exams. None of them used graph theory to extract functional
information of fMRI, but pulled out other types of information from fluorodeoxyglucose positron
emission tomography (FDG-PET). Moreover, relying on the assumption, shared by the imaging
community, that given a high number of features, a classifier would perform better, this work also
investigates the combined use of the MRI- and fMRI-derived features, together with the Mini Mental
State Examination (MMSE), to investigate differences between AD and HC subjects. In this work,
the MMSE is employed instead of other clinical indexes, such as the Neuropsychiatric Inventor
(NPI-Q) [29] or the Clinical Dementia Rating (CDR) [30]. The chosen cognitive screen is known to
suffer from unstable inter-rater reliability and from a limited score range; however, it is free, widely
available, quick to administer, and allows experts and non-experts to measure the general cognitive
ability, while allowing the comparison between different studies [31].
In this paper, the data were extracted from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database, consisting of 33 AD patients and 36 healthy controls. The MRI data were processed
with the Statistical Parametric Map (SPM) segmentation software to extract the structural feature, while
the BOLD signal from fMRI exams was exploited to evaluate connectivity measures through the graph
theory. The synthesis of the findings derived from MRI and fMRI data processing, through Spearman
correlation analysis between the Clustering Coefficient (CC) and GMV, can provide clinicians relevant
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clinical information about AD diagnosis. Moreover, for the first time, to the best of our knowledge, we
evaluated the possibility of correlating the GMV with the CC.
Finally, the measurements from three data, i.e., MRI, fMRI, and MMSE, were combined to
discriminate between AD and HC, through a Support Vector Machine (SVM). The findings presented
in this work demonstrate that, instead of exploiting one type of measurement, using the combined and
synergistic information from different imaging techniques (i.e., fMRI and MRI) and the clinical data
from MMSE enhanced the AD classification, with an accuracy of 95.65%, a sensitivity of 93.93%, and a
specificity of 97.22%. In fact, with a unimodal classification method, it is possible to obtain an accuracy
of 62.32%, a sensitivity of 66.66%, and a specificity of 58.33% for fMRI; and an accuracy of 50.72%, a
sensitivity of 30%, and a specificity of 69.44% for MRI.
2. Methods and Procedure
2.1. Magnetic Resonance Imaging
The need to extract biological information from intact biological systems using MRI and fMRI
introduced new technologies that allowed the study of human brain activity with greater detail and
resolution [32]. MRI offers more tissue contrast possibility than other radiological methodologies,
such as computerized tomography. This is possible by properly setting the time in which the
Radiofrequency (RF) impulsive excitement is produced and its derived signal is registered. The
contrast helps in discriminating different biological tissues and structures. However, it depends on
both the longitudinal relax time (T1) and transversal relax time (T∗2) [32] (T1 is the time necessary to
recover 63% of the longitudinal magnetization present before the RF impulse [4,32]).
In MRI, high T1is necessary to distinguish white matter, gray matter, and cerebrospinal liquid. T2
is the time required for the transversal magnetization vector to decrease at 37% of the maximum of
its intensity [4]. In MRI, low T2 are necessary to distinguish the three above-cited cerebral tissues [4].
As a matter of fact, to perform studies on AD using MRI images, data acquired with high T1 and low
T2 are necessary [4]. With these settings, the structural features can be adequately evaluated [4,32].
The MRI possibilities are often limited by the achievable SNR and the Contrast-to-Noise Ratio
(CNR). Both the SNR and CNR have been shown to increase with the static magnetic field strength
B0 [32]. Besides the influence of the magnetic field B0, the SNR is affected by other parameters,
such as Time Echo (TE), Time Repetition (TR), Flip Angle (FA), slice thickness, and matrix size [4,32].
The work of Coriasco et al. [4] contained further details about these parameters and their influence
on SNR. The intensity of the magnetic resonance signal is defined by the tissue volume. Indeed,
high tissue volumes produce an intense MR signal, which in turn increases the SNR. However, this
MRI measurement involves the so-called partial volume effect, which consequently lowers the image
resolution levels [33]. This is a relevant aspects in the elaboration of MRI images. In fact, the poorer
SNR of thin slices can be compensated to some extent by increasing the number of acquisitions or by a
longer TR [34]. Considering the work of Pohmann et al. [35], the SNR strictly depends on T1, T∗2 , TR,
TE, FA, and the sensitivity of the receiver coil.
Since this work made use of morphological data arising from MRI, the influence of all the cited
parameters [4,32,35] was critically considered when patients and images to analyze were selected.
2.2. Magnetic Mechanism of the BOLD Signal
The BOLD signal represents the hemodynamic response of cerebral activation [36]. Several studies
demonstrated that BOLD signal alterations represent a complex interplay between changes in the
metabolic rate of cerebral blood volume, blood flow, and oxygen consumption rate [1,36]. In fact,
the increased neuronal activity induces modifications in local vasculature and thus causes changes in
the deoxyhemoglobin (dHB) concentration [36].
The dHB and the oxyhemoglobin present paramagnetic and diamagnetic behavior, respectively,
leading to a shift of the local magnetic susceptibility [1]. In MRI, the material magnetization is directly
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proportional to the strength of the magnetic field [4]; hence, different magnetic responses provoke
different signals in MRI. Logothetis [3] demonstrated that the dHB induces field inhomogeneity and
neural activity, resulting in BOLD signal reduction.
The importance of the temporal preprocessing step for the BOLD signal was underlined in [37].
In our study, preprocessing steps are implemented using the CONNtoolbox. This allows specifying
possible temporal confounding factors, such as movement parameters and artifacts, and BOLD signals
obtained from noisy ROIs, such as White Matter (WM) and Cerebrospinal Fluid (CSF). Each temporal
confounding factor cn(t) is then regressed from the BOLD signal, called BOLD(v, t), at each voxel as
follows [37]:
BOLD(v, t) = BOLD ∗ (v, t)−
N
∑
n=1
an(v) · cn(t)−
K
∑
k=1
Mk
∑
n=1
bkn(v) · dkn(t) (1)
where BOLD ∗ (v, t) is the observed bold signal at voxel v and time t, while N is the number of temporal
confounds, and dk(t) are confound s from K noise ROIs, each characterized by Mk components of the
magnetization signal from each noise ROI.
The resulting residual BOLD signals are band-pass filtered (0.001 Hz–0.01 Hz). Mathematical
details are shown in Whitfield-Gabrieli et al. [37].
2.3. Data Acquisition and Preprocessing
All subjects used in this study were selected from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database. Data were selected based on the availability of the resting-state fMRI dataset for
age-matched healthy normal subjects and AD patients. A total of 69 subjects, 33 Alzheimer’s disease
(18 females, 15 males, age± SD = 72.72± 7.52 years, mini-mental state = 22.6667± 2.45, with a median
value of 22) and 36 healthy controls (21 females, 15 males, age ± SD = 72.51 ± 5.40 years, mini-mental
state = 26.6667 ± 1.36, with a median value of 29), of the ADNI-2 database were considered. For each
subject, only one acquisition was employed. The first acquisition of each subject was used, resulting in
a total of 69 acquisitions. Subjects’ demographic data are summarized in Table 1.
This database includes more subjects (around one thousand). However, not every subject presents
both morphological and functional images. Furthermore, some patients in the database may be initially
classified as AD (or HC), and then, their clinical status is changed. Those patients were excluded
from our study, i.e., we employed subjects that did not change their ADNI classification. Moreover,
a subject can present more MRI and/or fMRI acquisitions taken at different time steps. The data
used in this study were the only that presented contemporary anatomical MRI, functional MRI, and
MMSE for each acquisition in the ADNI database. The MMSE feature was employed in this study
because it is an accurate indicator of the clinical status and since it is widely used in clinical practice
and largely available for most of the subjects included in the ADNI database. Not all subjects from
the ADNI database presented the NPI-Q and/or the CDR indexes [29,30]. Additionally, as regards
the Mild Cognitive Impairment (MCI) subjects contained in the database, it should be noted that they
present only anatomical MRI or fMRI data, and for this reason, we did not include them in our study.
Moreover, in this work, images acquired with the same machine model and sequences were used
to avoid problems caused from using different apparatuses and to overcame bias, as well as other
problems due to different acquisition methods [4,32,35].
A major claim related to the number of subjects used in this study (i.e., 69) could be that the
dataset dimension is not sufficient for both statistical analysis and the employment of a supervised
approach for patients’ classification. However, from the current available literature, studies such
as [23,38] have used a number of subjects between 19 and 28 to investigate the differences between AD
patients and healthy subjects. Therefore, the use of a dataset 2.5-times larger should be regarded as an
added value. On the other hand, studies make use of a spread and wide dataset (max. six hundreds
patients) to perform statistical analysis, investigate the pathology using the graph theory or rely on
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automatic classification algorithms [26,39,40], and have employed a single imaging technique [41,42],
i.e., or MRI or fMRI or PET were used, but never combined together. Moreover, many of them specify
the conditions used for all subjects, which would surely be different, thus probably leading to a bias
in their results. Our paper has the aim of establishing the effectiveness of analyzing morphological,
functional, and clinical features in AD subjects in a synergistic way using a reliable dataset.
Resting state data and structural MRI scans were acquired with a 3.0 T Philips Medical System
scanner. The acquisitions were performed by ADNI according to its acquisition protocol [26].
The MRI data included high-resolution T1-weighted scans and an 8-channel receive-only head coil.
The parameters included: sagittal plane, slices = 170, TR = 6.77 ms, TE = 3.13 ms, TI= 0 ms, FA = 9◦,
matrix = 256 × 256, and voxel size = 1.0 × 1.0 × 1.2 mm3. All the resting state scans consisted of 140
functional volumes and were obtained while participants were resting in the scanner with eyes open.
The parameters included: TR = 3000 ms, TE = 30 ms, flip angle = 80◦, slice thickness = 3.313 mm, and
48 slices. Resting state images and structural scans were elaborated in Nifty format [43].
Table 1. Demographic and neuropsychological characteristics of the subjects.
HC Subjects AD Patients p-Value
Number of subjects 36 (21 F/15 M) 33 (18 F/15 M) p > 0.99 1
Age, years 72.51 (±5.40) 72.72 (±7.52) p > 0.05 2
MMSE 26.6667 (±1.36) 22.6667 (±2.45) p = 2.828×10−12 3
1 The p-value was obtained by the Pearson χ2 two-tailed test; 2 the p-value was obtained by a two-sample
two-tailed t-test; 3 the p value was obtained by the Pearson χ2 two-tailed test.
The images were processed using the CONN functional connectivity toolbox v15.a (nitrc.org,
Version 02142, Cambridge, MA, USA). This software exploits SPM routines to perform structural and
functional analysis. The preprocessing procedures are summarized in Figure 1. The first step was to
realign the MRI structural data to undo the effects of subject movements during the scanning session.
The differences between each successive scan and a reference scan, which is the average of all scans in
the time series, was minimized [44].
Afterwards, the data were transformed using linear warps into a standard anatomical space, the
Montreal Neurological Institute (MNI) space [45]. A slice timing correction step was necessary to
compensate for slice acquisition delays, which may add up to significant temporal shifts between the
expected and the actually measured BOLD signal [46]. Finally, it was useful to co-register (to realign the
256 × 256 MRI images with the 64 × 64 fMRI images to work in a unique reference frame) functional
and anatomical images [47]. We also included a scrubbing step for both motion artifacts and outliers
in fMRI images. The Artifact Detection Tools (ART) software (nitrc.org) was used to identify scans
affected by movement-related artifacts. Then, functional images were smoothed using a Gaussian
kernel of 8 mm FWHM. The movements and the physiological noise were removed by linear regression.
More precisely, the noise source considered was the signals from white matter and cerebrospinal fluid,
the six head motion parameters, and the outlier scans detected during the scrubbing process [37].
Then, the preprocessed images were bandpass filtered to 0.001 Hz–0.01 Hz to reduce the noise.
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Figure 1. Preprocessing and elaboration steps for MRI and fMRI images.
2.4. Image Segmentation with SPM
The segmentation is a process in which the image is divided into homogeneous and
non-overlapping regions, where pixels or voxels have similar attributes such as intensity or color [48].
In MRI brain analysis, brain tissue should be classified into three tissue types, namely GM, WM,
and CSF [48]. This distinction can be performed employing several different methods, e.g., manual
segmentation, intensity-based methods, atlas-based methods, surface-based methods, and hybrid
segmentation methods [48]. However, none of them is universally accepted in literature.
Therefore, in this study, the SPM automatic intensity-based Gaussian segmentation was employed
to recognize brain structures of interest and to use them for further analysis. In this method, each tissue
class is modeled by a Gaussian distribution [48] and the histograms of brain MRI images have three
main peaks corresponding to the three main tissue classes. These three peaks allow distinguishing the
brain tissues and performing the correct operation of segmentation. This approach uses a “modified
Gaussian Mixture Model” (GMM) [49], which is a standard technique widely used by many tissue
classification algorithms [50]. The main advantages of the standard GMM are the easy implementation
and the small number of parameters that can be efficiently estimated [49,50].
2.5. Brain Volume Calculation and Mask Construction
After the segmentation, the brain tissue images were used to quantify the whole brain volume
and the intracranial volume. The whole brain volume was calculated as the sum of the volume of GM
and WM; whereas the intracranial volume was calculated as the sum of GM, WM, and CSF.
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The total brain volume was normalized for the whole intracranial volume to eliminate gender
disparity [51]:
Vn =
WM + GM
WM + GM + CSF
(2)
In fact, as can be seen in Figure 2a,c, males and females presented different total brain volumes
(p < 0.05). After normalization, such a difference fell, as shown in Figure 2b,d (p > 0.05). These results
strongly agreed with those found in [52]. Afterwards, employing the Wake Forest PickAtlas software
(fmri.wfubmc.edu) [53], the masks were limited to a priori Regions Of Interest (ROIs) through the
AAL (Automated Anatomical Labeling) atlas [45]. This is one of the possible atlases to be used to
extract masks, and it is often employed for studies involving Alzheimer’s and MRI [54,55] or fMRI [56].
This atlas includes 90 ROIs (45 per hemisphere). These masks were employed to quantify ROI volume
and connectivity as in [54,55]. The whole brain, intracranial, and ROIs volume were determined
with the get_totals script (cs.ucl.ac.uk), such as in [57,58]. This script takes one segmented MRI set,
i.e., all the images for a given brain tissue, as input and then returns its volume expressed in mm3.
Furthermore, to quantify ROI volume, the script takes the GM image and the ROI mask, and then, it
calculates the intersection between these images, finally returning its volume in mm3.
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Figure 2. Statistical differences in whole brain volume between male and female subjects for the HC
group (a) and AD group (c) (p < 0.05). After whole brain normalization (Vn), the scatter plots show a
similar range of variation for both HC (b) and ADs (d) subjects (p > 0.05).
2.6. Connectivity Matrix and Network Measure
As stated in Section 2.2, the BOLD signals were extracted from fMRI images. Each signal was used
to create connectivity matrices of 90 × 90, in which each row and each column stood for one ROI of the
atlas. Each value in the matrices represented the functional connectivity. The functional connectivity
is defined as the statistical dependencies among remote neurophysiological events [36,59], and it is
measured with Pearson’s correlation coefficient between two BOLD signals, mathematically [60]:
r =
σpq
σpσq
(3)
where σpq is the covariance of the two BOLD signals, and σp and σq are the standard deviations of the
pth and qth signal, respectively. The connectivity matrices, shown in Figure 3, were used to perform
the network measure, i.e., the calculation of a clustering coefficient.
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Figure 3. Connectivity matrices for the (a) AD group, (b) HC group, and (c) the difference HC-AD.
Other studies [61,62] demonstrated that this parameter is useful to discriminate the patient from
the healthy control in Alzheimer’s disease. Similarly to [61], the clustering coefficient was used with
another graph measure, path length, to evaluate the global organization of large-scale networks or the
small world index and then evaluate the AD progression [63]. In our study, the clustering coefficient
was used in combination with the relevant morphological brain feature to estimate the possible
correlation between functional and morphological information in AD patients and to discriminate
healthy controls from patients.
These matrices showed the mean functional connectivity in the AD group (Figure 3a), in HC
subjects (Figure 3b), and the difference between the HC and AD groups (Figure 3c). Figure 3c displays
that there was a difference between the means of the correlation coefficients. This difference arose for
several ROIs, but not for all of them. The CC of a vertex represents the likelihood that its neighbors are
connected [64]. The clustering coefficient Ci of a vertex i with degree ki is usually defined as the ratio
of the number of existing edges (ei) between the neighbors of i, and the maximum possible number of
edges between the neighbors of i [16]:
Ci =
2ei
ki(ki − 1) (4)
This measurement was calculated with the Brain Connectivity Toolbox (BCT)
(n-connectivity-toolboox.net).
2.7. Statistical Analysis
All statistical analyses in this study were performed using the MATLAB Statistic Toolbox. In order
to test if the normalized volume and GMV were significantly different among the HC and AD
groups, a Mann–Whitney U-test was performed. When multiple comparisons are made between
data, false positives ought to be thrown back through appropriate corrections, such as Bonferroni’s
correction [65] or the False Discovery Rate (FDR) [66]. In this analysis step, only Bonferroni’s correction
was performed because it is more conservative [28]. Finally, to test the correlation between MMSE and
GMV and between CC and GMV, Spearman’s correlation was employed.
2.8. Support Vector Machine Classifier
As discussed in the Introduction, to help the clinicians to investigate the AD status, the use
of machine learning has been explored in the literature [27,28]. Among the available supervised
approaches, Support Vector Machine (SVM) is an efficient supervised learning method, which can
organize large dimensional data classification [67]. This linear classifier is very efficient in working with
two-class linearly-separable tasks, i.e., with data of the binary class [67]. The classification operates
finding the hyperplane with the maximum possible margin between the two classes.
The capability and usefulness of the SVM classification method to discriminate AD patients
from healthy ones was demonstrated in other studies [27,28,68]. However, it must be stressed that
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these works made use of structural brain features only, i.e., morphological information derived from
MRI [68]. Even when a reduced number of feature is employed, this method should be regarded as
a partial and limited approach to the development of a reliable diagnostic tool.
In contrast with other studies, which used different imaging modalities, such as FDG-PET [27]
or investigated CSF [28], the approach proposed in this paper exploits fMRI. In these studies [27,28],
which presented both anatomical and another type of functional images, the number of subjects was
comparable to the one used therein. In fact, in other studies that used MRI, such as [26,39,41], subjects
presented only morphological images. Another study used only fMRI acquisition, presenting 40
subjects, 20 ADs and 20 HCs [42]. All these considerations allowed us to say that our number of
subjects was sufficient for this type of analysis. The approach proposed in our paper may be of interest
for other researchers, which could access a larger dataset.
To train the SVM classifier, we used the leave-one-out method, as in [27,42]. In this case,
the analysis was repeated for each subject: in every iteration, one sample was left out to test the
classifier, and the remaining subjects were fed to the classifier for training [69]. The procedure was
repeated until all subjects were used at least once as the test sample. In this study, the SVM classifier
was implemented in MATLAB.
Three different SVM classifiers were tested. Firstly, the unimodal approach was assessed.
Therefore, two different SVM systems were trained, one using the MRI measurements and the other
one employing the fMRI-derived feature. Then, the MRI, fMRI, and MMSE information was combined
to train a multimodal SVM classifier. The MMSE indicator was strongly correlated with the pathology
and thus could favor the investigation between HC and AD subjects [29,31,70].
3. Results
The data used in this study were obtained from the ADNI open database, for a total of 69
acquisitions of AD and HC subjects. The goal of this paper was to compare AD patients with a group
of HC to evaluate their morphological and functional differences, both through the correlation analysis
and through the SVM classification.
First, a Mann–Whitney U-test was performed to explore the statistical differences of the
normalized whole brain volume between the AD patient group and the control group [71]. In Figure 4,
the results show that there was a significant difference between the two groups (p = 0.0011, z = −3.26).
Moreover, AD patients presented a lower volume when compared with HCs. The findings from [5,20]
supported our results and suggested that AD is related to a lower brain volume with quantifiable
differences with respect to the HC subjects.
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Figure 4. Statistical differences in normalized whole brain volume between HC and AD groups
(p < 0.05).
Furthermore, 36 ROIs presented a lower GMV (p < 0.05) in AD patients compared with HC.
Even in this case, a Mann–Whitney U-test was performed. After Bonferroni’s statistical correction,
only two ROIs survived, the right rolandic operculum and the left superior temporal gyrus. Given
the AAL atlas, some of the regions that did not survive after Bonferroni’s correction (the discarded
34 ROIs) belonged to frontal lobe, as is reported in Table 2, which is involved in cognitive function.
Supposedly, these ROIs are affected by the pathology state [72]. Moreover, many of these regions
were found in other structural studies that used the ADNI database, such as insula [38], frontal cortex
[38,73], posterior cingulate cortex [23,73,74], hippocampus [73,75], fusiform [76], temporal lobe [38,73],
and, in particular, left middle temporal gyrus [45,76]. These confirm and validate our results.
As performed in other studies [76,77], the possible correlation between GMV and the cognitive
status, i.e., MMSE, across groups was studied. The AD patients had a MMSE score [78] of 12 ÷ 28,
whereas HC had an MMSE score of 24 ÷ 30. This analysis step was necessary to evaluate if cognitive
status was associated with structural status. Spearman’s correlation coefficient was used [79]. Across
groups, GMV was correlated to the MMSE score in 10 ROIs, as we can see in Table 3, but after
Bonferroni’s correction, no one survived. Even in this small-sized database, AD patients were
associated with lower values of MMSE, with respect to the HC subjects. The lower score of MMSE was
associated with a lower GMV in the left superior temporal gyrus (ρ = 0.3602, p = 0.0024), as shown in
Figure 5. This result shows that in AD subjects, the cognitive status was positively correlated with GM
atrophy. Thus, for the atlas and the dataset analyzed in this study, this finding probably implies that a
lower cognitive capacity is linked to a lower brain volume, which is the first consequence of pathology
in AD [80].
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Table 2. Regions with a significant difference in grey matter volume between AD and HC that did not
survive after Bonferroni’s correction.
Region Number Location p-Value
1 Precentral L 0.0259
2 Precentral R 0.0093
4 Frontal Sup R 0.0275
5 FrontlSupOrbL 0.0275
8 Frontl Mid R 0.0371
11 Frontl InfOperL 0.0061
12 Frontl Inf Oper R 0.000631
14 Frontl Inf TriR 0.0251
17 Rolandic Oper L 0.0011
29 Insula L 0.013
30 Insular R 0.00e-34
37 Hippocampus L 0.0087
43 Calcarine L 0.045
44 Calcarine R 0.0361
47 Lingual L 0.0214
48 Lingual R 0.0123
50 Occipital Sup R 0.0468
56 Fusiform R 0.0054
57 Postcentral L 0.0251
58 Postcentral R 0.0063
59 Parietal SupL 0.0495
60 Parietal Sup R 0.0315
61 Parietal Inf L 0.0284
62 Parietal Inf R 0.0093
63 Supramarginal L 0.0160
64 Supramarginal R 0.0115
65 Angular L 0.0166
66 Angular R 0.009
67 Precuneus L 0.010
68 Precuneus R 0.0131
73 Putamen L 0.0442
75 Pallidum L 0.0040
76 Pallidum R 0.0394
82 Temporal Sup R 0.0023
Table 3. Regions with significant correlation between grey matter volume and MMSE across AD and
HC groups.
Region Number Location ρ p-Value
11 Frontl Inf Oper L 0.2460 0.0416
12 Frontl Inf Oper R 0.27533 0.0221
17 Rolandic Oper L 0.2618 0.0298
18 Rolandic Oper R 0.3453 0.0037
29 Insula L 0.2455 0.0421
37 Hippocampus L 0.2783 0.0206
67 Precuneus L 0.261 0.0309
73 Putamen L 0.2601 0.0309
75 Pallidum L 0.2632 0.0289
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Figure 5. Correlation between GMV and MMSE within groups in the left superior temporal gyrus.
Successively, the correlation analysis between GMV and the clustering coefficient in the ROIs
was assessed. This step was necessary to evaluate if any possible correlation between structural and
functional information existed and can be exploited as a clinical feature to identify a possible difference
between the HC and AD groups. The analysis was performed considering the two groups separated
and then combining AD and HC subjects. This choice was aimed to identify if the correlation coefficient,
ρ, can be statistically significant for a given ROI and to understand in which measure it can contribute
to the knowledge of the differences between healthy control and diseased subjects, also when the two
classes are grouped and mixed. In the literature, nobody has demonstrated this possible relationship
using structural MRI and fMRI. Previous studies employed GMV as a covariate [23,73,74,81] or
evaluated the anatomical overlap between GM atrophy and functional disconnection [80].
Other techniques, such as diffusion MRI [24], were used to evaluate such a probable correlation.
In this work, across groups, the GMV and the CC were correlated in seven ROIs; after Bonferroni’s
correction, no ROI survived. From Figure 6a, higher GMV was associated with high CC in the
right supplementary motor area (ρ = 0.3107, p = 0.0096). Within the HC group, nine ROIs presented
correlation between GMV and CC. Higher GMV was associated with a higher correlation coefficient in
the left calcarine (rho = 0.4597, p = 0.0052), as shown in Figure 6b. Within the AD group, as observed
from Figure 6c, only four ROIs presented a correlation between GMV and CC. Higher GMV was
associated with a higher CC in the left hippocampus (ρ = 0.4014, p = 0.0213). Other results of the
correlation analysis are shown in Table 4. The findings from Table 4, considering the HC subjects,
indicated that the correlation coefficient of GMV and CC of both the supplementary motor areas and
the cuneus, the left calcarine, the middle-left occipital, and left angular were statistically significant.
When looking at the ρ between structural and functional information for these ROIs in the AD group,
it can be noticed that they did not survive the Bonferroni correction. Indeed, for the AD set, the
number of ROIs that presented a strong and significant correlation between CC and GMV was lower.
They were middle-left frontal, frontal inferior right operculum, left hippocampus, and left Heschl.
It can be inferred that considering a homogeneous group (or HC or AD), the correlation between
some ROIs was significant, but the ROIs were not the same. This can be relevant information, since
a positive correlation coefficient indicates that lower values of GMV are associated with lower CC
values, implying that the pathology determines differences in structural and functional features. When
AD and HC subjects were grouped, it can be observed, after Bonferroni’s correction, that most of
the ROIs with a statistically-significant correlation coefficient were areas that were not pointed out
when analyzing the other groups (left precentral, left and right angular, left paracentral lobule, and
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right putamen). However, for both the left and right supplementary motor area and the left cuneus,
significant results were found, as when the HC group was analyzed. It is evident that the GMV of these
ROIs can be associated with a strong relationship with the CC in healthy subject, even for AD patients.
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Figure 6. Correlation between the Clustering Coefficient (CC) and GMV (a) within groups in the right
supplementary motor area (ρ = 0.3107, σ = ± 1.998), (b) in the HC group in left calcarine (ρ = 0.4597,
σ = ±0.4787), and (c) in the AD group in left hippocampus (ρ = 0.4014, σ = ±0.7299). The three regions
with the highest correlation values are presented.
Table 4. Regions with significant correlation between Grey Matter Volume (GMV) and the Clustering
Coefficient (CC) across and with AD and HC groups. The area that survived Bonferroni’s correction is
highlighted in bold font.
ROI—Number and Description HC + AD HC AD
ρ p-Value ρ p-Value ρ p-Value
1 Precentral L 0.2417 0.0457 0.2981 0.0778 0.1340 0.4556
7 Frontal Mid L 0.2054 0.0904 0.0996 0.5619 0.3663 0.0367
12 Frontl Inf Oper R 0.2327 0.0545 0.0965 0.5742 0.3767 0.0314
19 Supp Motor Area L 0.2435 0.0440 0.3629 0.0175 0.0775 0.6669
20 Supp Motor Area R 0.3107 0.0096 0.3959 0.0175 0.1942 0.2777
37 L Hippocampus 0.4014 0.0213 −0.0337 0.8450 0.4014 0.0213
43 Calcarine L 0.1828 0.1326 0.4597 0.0052 −0.1334 0.4578
45 Cuneus L 0.2578 0.0327 0.4301 0.0094 0.0869 0.6294
46 Cuneus R 0.2178 0.0723 0.4461 0.0069 −0.0338 0.8519
49 Occipital Sup L 0.2102 0.0831 0.4417 0.0075 −0.0097 0.9578
50 Occipital Sup R 0.2337 0.0535 0.4571 0.0055 −0.0267 0.8826
51 Occipital Mid L 0.2162 0.0754 0.4309 0.0092 −0.0331 0.8548
65 Angular L 0.1127 0.3558 0.3514 0.0362 −0.0575 -0.7500
66 Angular R 0.1859 0.0464 0.2762 0.1031 0.1390 0.4388
69 Paracentral Lobule L 0.2887 0.0164 0.2046 0.2303 0.3225 0.0676
74 Putamen R 0.2575 0.0330 0.3040 0.0718 0.1922 0.2827
79 Heschl L 0.2288 0.0588 0.1292 0.4511 0.3606 0.0399
Figures 5 and 6 show the ROIs having the biggest correlation coefficient for each analysis. We
decided not to present all ROI graphics to allow a comprehensible reading. Moreover, in each graphic,
the correlation line and the standard deviation are depicted. The reader should note that the correlation
coefficient did not reach values higher than 0.75. However, in our case, Pearson’s coefficient was
influenced by several factors, such as the number of subjects and the clinical condition, i.e., the MMSE.
In fact, the distribution of the correlation coefficient values fell within the range observable in other
literature surveys [74].
Finally, the SVM classification was tested. Firstly, the performance of the unimodal classification
method in the identification of AD from the healthy controls was tested, based on MRI or fMRI.
Specifically, when using fMRI, a unimodal classification method, it was possible to achieve a
classification accuracy of 62.32%, a sensitivity of 66.66%, and a specificity of 58.33%. On the other hand,
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when relying on MRI only, the classification of AD subjects from HC for the mono-modal method
showed a classification accuracy of 50.72%, a sensitivity of 30%, and a specificity of 69.44%.
As a comparison with the previous two classification methods, the combined measurements of
MRI, fMRI, and MMSE were used to train the SVM classifier. For each subject, the set of 90 features
coming from MRI, GMV from 90 ROIs, 90 features derived from fMRI, clustering coefficient from
90 ROIs, and one feature from MMSE, was concatenated. As can be noticed from Table 5 and Figure 7,
the combination of MRI, fMRI, and MMSE measurements achieved a more accurate classification and
discrimination between AD and HC. In this case, the method could achieve a classification accuracy of
95.65%, a sensitivity of 93.93%, and a specificity of 97.22%.
Table 5. Comparison of different SVM classifiers’ performance for diverse diagnostic data.
Methods Accuracy (%) Sensibility (%) Specificity (%)
fMRI 62.32 66.66 58.33
MRI 50.72 30.02 69.44
MRI + fMRI + MMSE 95.65 93.39 97.22
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
False Positive Rate
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
T
ru
e
 P
o
s
it
iv
e
 R
a
te
ROC for AD vs HC classification
MRI
fMRI
MRI-fMRI-MMSE
Figure 7. ROC curves of the different SVM classifiers trained using MRI, fMRI, and combined diagnostic
information for recognizing AD subjects.
While other studies [25,82] applied the SVM unimodal classification method or exploited images
obtained from different imaging techniques [27,28], our study implemented a multimodal classification
from the MRI and fMRI method combined with MMSE. The results derived from training the SVM
with MRI, fMRI, and MMSE data allowed us to infer that the approach proposed in this paper is
valuable and can be of potential interest to clinicians and researchers. The presented method can be
adapted to carry out a similar analysis to evaluate if differences between AD and MCI patients exist.
To this aim, the use of the MMSE as additional information and the investigation of its relationship
with MRI- and fMRI-derived data can support AD research.
4. Conclusions
In this paper, morphological MRI and functional MRI images’ processing was analyzed to
verify the possibility of correlating anatomical and functional data for AD and HC subjects. First,
we compared normalized whole brain volume between the HC group and AD group, which presented
a lower value of this parameter. Furthermore, 36 ROIs exhibited a negative change of the GMV in AD
patients compared with the HC ones. These regions are known to be involved in functions affected
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by the pathology progression [72,83]. Furthermore, regarding the possible correlation between GMV
and cognitive status, i.e., MMSE, within groups, we had positive correlation coefficients between
GMV and MMSE in left superior temporal gyrus. Our results agree with a previous study [84],
where positive correlation between MMSE and a volumetric measure, i.e., volumes of deep GM,
was reported. This demonstrates that pathology differences are strictly linked to a minor brain volume
in AD patients and to physiological aging in HC. Successively, the potential association between GMV
and CC in the ROIs was analyzed to correlate anatomical and functional results.
In fact, in the literature about AD research, to the best of our knowledge, nobody has demonstrated
this promising relationship. The AD group showed a positive correlation in 4 ROIs, while in the HC
group, there were nine ROIs correlated. This showed the relationship between morphological and
functional data. On the other hand, this did not allow direct classification between the two groups,
but only highlights a possible relationship between function and structure; hence the necessity to
perform the SVM classification. In our study, we put in prominence the investigation of the differences
between the AD group and HC, combining the structural, functional, and clinical features, through
MRI, fMRI, and MMSE, respectively. Indeed, the unimodal classification methods, which use only one
feature, showed poor accuracy and low values of sensitivity and specificity. Moreover, unlike other
studies [27,28], we used the fMRI technique. The use of BOLD signals and derived measurements
from fMRI allowed a less troublesome investigation since this approach does not employ radiative
contrast agents or require the acquisition of liquid biological samples [27,28]. Moreover, at the same
time, it provides helpful information related to AD status. Moreover, while other studies [25,82] used
only MRI images, we proposed a multimodal method that combines MRI, fMRI, and MMSE with an
increased accuracy.
Additional studies could provide further analysis and could confirm these findings. The brain
volumes can be correlated with other metrics, which can be used to derive other features, e.g.,
the correlation of GM with path length measurements. This would further help to understand
the link between structure and function in AD subjects. Instead, through the use of a classifier, it
was possible to discriminate AD patients from healthy controls, and this could be a potential use in
clinical applications.
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